European HealthTech this week is dominated by regulatory fine‑tuning around AI in devices, fresh EU‑level funding calls, and continued capital and grant focus on AI‑enabled care delivery and data platforms. European MedTech this week is being shaped by MDR/IVDR simplification moves, the hardening EUDAMED timetable, and EU‑level initiatives (including the Biotech Act and IHI Call 12) that favour data‑rich,

European HealthTech this week is being shaped by fresh EU-level funding calls for digital health and AI, tightening but slightly simplified device and AI regulation, and continued emphasis on compliance‑driven M&A and scaling of AI decision‑support. Capital is available but flowing selectively into data‑rich platforms, cross‑border care models, and AI‑enabled diagnostics that can navigate the emerging AI Act / MDR / HTA stack.

The European MedTech and HealthTech valuation landscape in October 2025 exhibits significant divergence by sub-sector, with a clear premium placed on innovative, high-growth, and recurring revenue business models, especially those powered by AI. Here is a breakdown of the valuation trends and multiples by sub-sector..